Activation of midline thalamic nuclei by antipsychotic drugs.
The thalamus has been proposed as a site which may be involved in the production of the syndrome of schizophrenia and the response of schizophrenic symptoms to treatment. These studies test whether, consistent with this hypothesis, the activation of thalamic nuclei is a shared property of neuroleptic antipsychotic drugs. Rats were given single doses of the typical high and low potency neuroleptics haloperidol (1 mg/kg) and chlorpromazine (20 mg/kg), the atypical neuroleptics thiroridazine (20 mg/kg) and clozapine (20 mg/kg), the specific dopamine antagonist raclopride (3 mg/kg), the mixed dopamine/serotonin antagonist risperidone (3 mg/kg) or drug-free vehicle. Increased expression of Fos-like protein was utilized as a marker of cellular activation. All drugs tested, including typical and atypical antipsychotic agents, led to similar effects on the midline thalamic paraventricular, centromedian and rhomboid nuclei and the nucleus reuniens. These results suggest that midline thalamic nuclei may participate in neural circuits mediating some of the shared effects of antipsychotic drugs.
Cohen
B M
BM
McLean Hospital, Mailman Research Center, Molecular Pharmacology Laboratory, Belmont, MA 02178-9106, USA.
Wan
W
W
Froimowitz
M P
MP
Ennulat
D J
DJ
Cherkerzian
S
S
Konieczna
H
H
D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D006220:Haloperidol / Q000494:pharmacology; D008297:Male; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D020891:Raclopride; D051381:Rats; D017207:Rats, Sprague-Dawley; D018967:Risperidone / Q000494:pharmacology; D012457:Salicylamides / Q000494:pharmacology; D013787:Thalamic Nuclei / Q000187:drug effects* / Q000378:metabolism; D013881:Thioridazine / Q000494:pharmacology
D014150:Antipsychotic Agents; D016760:Proto-Oncogene Proteins c-fos; D012457:Salicylamides; D020891:Raclopride; D006220:Haloperidol; D018967:Risperidone; D013881:Thioridazine